You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

CLINICAL TRIALS PROFILE FOR RASAGILINE MESYLATE

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for rasagiline mesylate

Subscribe to access the full database, or Subscribe
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00104273 ↗	Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD)	Completed	Eisai Inc.	Phase 2	2004-08-01	The purpose of this study is to evaluate the safety, tolerability, and efficacy of two dose levels of rasagiline mesylate versus placebo in patients with mild-to-moderate Alzheimer's Disease who are taking Aricept.
NCT00104273 ↗	Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD)	Completed	Teva Branded Pharmaceutical Products R&D, Inc.	Phase 2	2004-08-01	The purpose of this study is to evaluate the safety, tolerability, and efficacy of two dose levels of rasagiline mesylate versus placebo in patients with mild-to-moderate Alzheimer's Disease who are taking Aricept.
NCT00104273 ↗	Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD)	Completed	Teva Pharmaceutical Industries	Phase 2	2004-08-01	The purpose of this study is to evaluate the safety, tolerability, and efficacy of two dose levels of rasagiline mesylate versus placebo in patients with mild-to-moderate Alzheimer's Disease who are taking Aricept.
NCT00203034 ↗	Multicenter Study of Rasagiline in Parkinson's Disease Patients Using Levodopa and Experiencing Motor Fluctuations	Completed	Teva Branded Pharmaceutical Products R&D, Inc.	Phase 3	2000-05-01	Study for patients currently using Levodopa/Carbidopa who will be assigned to receive either Rasagiline or Placebo
NCT00203034 ↗	Multicenter Study of Rasagiline in Parkinson's Disease Patients Using Levodopa and Experiencing Motor Fluctuations	Completed	Teva Pharmaceutical Industries	Phase 3	2000-05-01	Study for patients currently using Levodopa/Carbidopa who will be assigned to receive either Rasagiline or Placebo
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for rasagiline mesylate

Condition Name

Chart
Table

Condition Name for rasagiline mesylate
Intervention	Trials
Parkinson's Disease	11
Alzheimer's Disease	1
Dementia	1
Multiple System Atrophy	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for rasagiline mesylate
Intervention	Trials
Parkinson Disease	12
Dementia	1
Parasomnias	1
Alzheimer Disease	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for rasagiline mesylate

Trials by Country

Map
Table

Trials by Country for rasagiline mesylate
Location	Trials
United States	68
Canada	12
Israel	4
South Africa	3
Germany	3
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for rasagiline mesylate
Location	Trials
California	6
New York	5
Illinois	5
Pennsylvania	4
Texas	4
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for rasagiline mesylate

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for rasagiline mesylate
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	7
Phase 2	2
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for rasagiline mesylate
Clinical Trial Phase	Trials
Completed	14
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for rasagiline mesylate

Sponsor Name

Chart
Table

Sponsor Name for rasagiline mesylate
Sponsor	Trials
Teva Branded Pharmaceutical Products R&D, Inc.	12
Teva Pharmaceutical Industries	12
Teva Neuroscience, Inc.	3
[disabled in preview]	3
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for rasagiline mesylate
Sponsor	Trials
Industry	30
Other	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.